Bristol-Myers: FDA expands Sprycel in pediatric leukemia
(CercleFinance.com) - Bristol-Myers Squibb's Sprycel has now been approved, in combination with chemotherapy, for a second type of pediatric leukemia, the US drugmaker said on Thursday.
The US Food and Drug Administration (FDA) has expanded the tablet's indication to include the treatment of pediatric patients of one year of age and older with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia, the company said.
Sprycel's previous indication was for children with Ph+ chronic myeloid leukemia in chronic phase.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The US Food and Drug Administration (FDA) has expanded the tablet's indication to include the treatment of pediatric patients of one year of age and older with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia, the company said.
Sprycel's previous indication was for children with Ph+ chronic myeloid leukemia in chronic phase.
Copyright (c) 2019 CercleFinance.com. All rights reserved.